Co-Founder & CEO
Ron Alfa is a physician scientist at the forefront of leveraging technology to tackle unmet therapeutic needs in medicine. He is Co-Founder and CEO of NOETIK, a next generation precision oncology company using multimodal foundation models pre-trained on large-scale human tumor data to discover cancer therapeutics. Prior to founding Noetik, Ron was Senior Vice President, Head of Research and acting-CSO at Recursion, where he led the company’s scientific organizations and portfolio strategy. At Recursion, he led portfolio and platform builds across rare disease, neuroscience, oncology, and immunology, and was responsible for advancing multiple therapeutic programs from discovery to clinical development. Ron holds an MD and PhD from Stanford University School of Medicine, where he completed his doctoral work in Neuroscience, and has a MA in History of Medicine from UCL.